AbbVie's Rinvoq notches Crohn's disease win amid classwide JAK safety concerns 'We're getting there': LGBTQ+ progress in biotech lingers in the 'diagnose' stage BD finalizes name and leadership for its billion-dollar diabetes spinoff After court-ordered injunctions, Cleveland Clinic, HCA and other providers hit pause on workforce vaccine mandates Genetic variant linked to Amish community could pave way for new heart disease therapies Merck taps Thermo Fisher to manufacture COVID pill in Canada for global rollout push FDA spots 26 tests where omicron detection requires further confirmation Biohaven pain spray aces test as C-suite shake-up sees incoming CFO, chief in chairman role Hack targets Planned Parenthood, exposing personal information of 400K patients Could Viagra prevent and treat Alzheimer's? Cleveland Clinic team shows its potential BenevolentAI to take drug discovery tech public in Europe's largest SPAC deal, valued at €1.5B Lawmakers to unveil findings on long-running drug pricing probe and discuss reforms HHS: Telehealth use in Medicare increased 63-fold last year with behavioral health increasing the most Adicet soars on early responses to gamma delta CAR-T therapy Featured Story | By Fraiser Kansteiner As AbbVie's best-selling drug Humira inches toward a 2023 patent cliff, the company has pinned its growth hopes on its next-gen offerings Rinvoq and the IL-23 inhibitor Skyrizi. On Monday, Rinvoq notched a win in a tricky-to-treat group of Crohn's disease patients. read more |
| |
|---|
|
| | The PerkinElmer Biotech Bundle is deployed via Amazon CloudFormation and provides the most advanced analytical package for drug discovery available today. Affordable and easy to get started. Learn more. |
Top Stories By Kyle LaHucik The biotech industry is "getting there" in terms of advancing LGBTQ+ inclusion, but it's an effort that remains in the early innings. Fierce Biotech spoke with more than 20 LGBTQ+ leaders in biopharma to learn where the industry stands on incorporating the LGBTQ+ community into its diversity and inclusion work. read more By Conor Hale BD has settled on a new name for its new company, the independent spinout that will house its billion-dollar diabetes care business. Embecta is set to launch as its own, publicly traded brand in the second quarter of 2022 after almost a century of supplying a portfolio of insulin pens and syringes under the BD banner. read more By Dave Muoio Several health systems said they will not require employees to be vaccinated as the Biden administration's industry-wide mandate plays out in court. read more By Kyle LaHucik Researchers at the University of Maryland say a genetic variant linked to the Old Order Amish community in Pennsylvania reduce levels of LDL cholesterol and a blood-clotting protein. The findings could lead to new paths for preventing or treating cardiovascular disease. read more By Joseph Keenan Merck & Co. signed a deal under which molnupiravir production will be conducted at Thermo Fisher Scientific’s Ontario, Canada, facility. If approved, the drug will be distributed to Canada, the U.K. and markets in the European Union, Asia Pacific and Latin America. The Ontario plant is one of only three production sites for the therapy in the world. read more By Conor Hale An initial analysis by the FDA of commonly used COVID-19 tests found that while the omicron variant may produce an identifiable pattern in their results, that pattern alone is not enough to make a definitive omicron diagnosis. The agency recommended healthcare providers prioritize the full sequencing of those positive samples. read more By Ben Adams Biohaven is eyeing filing for approval early next year for its experimental pain spray after new data showed it hit its primary endpoints in a phase 3 test. read more By Rebecca Torrence A cyberattack on Planned Parenthood’s Los Angeles branch exposed the personal information of about 400,000 patients between Oct. 9 and Oct. 17. The Los Angeles affiliate didn’t find any evidence the stolen information had been used for “fraudulent purposes,” the branch said in a letter to its patients. read more By Arlene Weintraub Using stem cell models derived from Alzheimer's patients, researchers at the Cleveland Clinic discovered that the erectile dysfunction drug Viagra (sildenafil) targets tau, one of the proteins implicated in the disease. They're now planning a phase 2 trial of Viagra in Alzheimer’s patients. read more By Andrea Park In the course of its combination with special purpose acquisition company Odyssey—which went public in a 300 million euro IPO of its own earlier this year—BenevolentAI will rake in up to 390 million euro in net proceeds. read more By Kevin Dunleavy On Thursday, the House Committee on Oversight and Reform will hold a hearing to present its findings on an investigation of the pricing strategies of U.S. companies producing the world's most expensive drugs. The committee also will assess how President Biden’s Build Back Better Act will reduce drug prices. read more By Robert King A new HHS study found that telehealth use in traditional Medicare increased 63-fold in 2020 compared to 2019, but did not fully offset a decline in healthcare utilization fueled in part by the pandemic. read more By Nick Paul Taylor Adicet Bio has laid down a marker for the nascent gamma delta CAR-T cell therapy space, reporting its off-the-shelf candidate ADI-001 triggered responses in a small clinical trial of B-cell non-Hodgkin lymphoma patients. Shares in Adicet jumped 45% to above $14 in premarket trading. read more | 